Pregabalin Capsule 150 mg (Pregabalin)
Pregabalin 150mg
Hard capsule · Prescription medication
Kooju Pharmaceutical Co., Ltd.
MFDS item code 201903069 · Approved 2019.05.13
This product's status changed to Expired on 2024.05.13. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures in epilepsy
This medication is used for the treatment of peripheral and central neuropathic pain in adults. It is also used as an adjunct for partial seizures with or without secondary generalization in patients with epilepsy. Additionally, it is effective in alleviating symptoms of fibromyalgia. In summary, this drug is used for neuropathic pain, adjunctive therapy for partial seizures in epilepsy, and the treatment of fibromyalgia.
This medication is administered orally, with or without food, with the total daily dose of pregabalin divided into 2 doses. Since this medication is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: A starting dose of 150 mg/day may be administered. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: A starting dose of 150 mg/day may be administered. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: A starting dose of 150 mg/day may be administered. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg-450 mg/day. The starting dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies were also conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys unchanged. Since its clearance is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. For women, multiply the result obtained from the above calculation by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an additional supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) / Total daily dose of pregabalin a / Dosing method / Starting dose (mg/day) / Maximum dose (mg/day) ≥60 / 150 / 600 / BID or TID ≥30-<60 / 75 / 300 / BID or TID ≥15-<30 / 25-50 / 150 / QD or BID <15 / 25 / 75 / QD Supplemental dose after hemodialysis / 25 / 100 / Single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified under the dosing method. b: The supplemental dose refers to an additional dose administered once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years of age or older) Dose reduction may be necessary in older adults with impaired renal function.
Children under 12 years of age: Use is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12-17 years: Use is not recommended because there are insufficient safety and efficacy data.
This drug may increase the risk of suicidal thoughts or behaviors, so if symptoms of depression, mood changes, or abnormal behavior occur during treatment, notify a healthcare professional immediately. Patients with allergies to this medication's components or genetic issues such as lactose intolerance should not take this medication. Diabetic patients should be cautious as weight gain may require adjustment of blood sugar control medication doses. If symptoms of angioedema, such as swelling of the face, mouth, or neck, occur, discontinue the medication immediately. Elderly patients should take care, as dizziness or drowsiness may increase the risk of falls or injury while taking this medication. Taking this medication may temporarily blur vision or cause changes in eyesight; consult a healthcare professional if symptoms occur. Abruptly discontinuing this medication may lead to withdrawal symptoms such as insomnia, headache, anxiety, and nausea, and should be gradually reduced under a doctor's guidance. Due to the potential for drug abuse or dependence, patients with a history of mental illness or substance abuse should use this medication cautiously. Patients with decreased kidney function may require dose adjustments of this medication. Patients with heart disease should be cautious during use, as symptoms of congestive heart failure may worsen when taking this medication. It is necessary to exercise caution when combining with other medications that have central nervous system depressant effects due to the risk of respiratory depression. Pregnant women should avoid this drug during the early stages of pregnancy due to the risk of fetal malformations, and women of childbearing age should use effective contraception. Lactating women should carefully consider whether to take this medication as it can be passed into breast milk and affect infants. Activities requiring concentration, such as driving or operating machinery, should be approached with caution after taking this medication, as dizziness or drowsiness may occur. In case of overdose, symptoms such as drowsiness, confusion, depression, and seizures can occur, and immediate medical attention should be sought.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to protect it from air and moisture, preferably at a temperature between 15 and 30 degrees Celsius. Proper storage helps maintain the efficacy and safety of the medication.
A hard capsule with white powder
30 capsules/bottle, 60 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Pregabalin 150mg
Hard capsule · Prescription medication
Kooju Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.